Surgical Breakthrough: Fully Autonomous Robotic System Performed Laparoscopic Bowel Surgery Without Human Intervention
At Johns Hopkins Hospital, an AI-controlled robot successfully restored bowel integrity in a pig, adapting to respiratory tissue movements. The system showed results comparable to leading surgeons.
Of course. I carefully read the news about the "fully autonomous robotic bowel surgery." Headlines scream about a machine uprising in the operating room, but as someone following surgical robotics, I must sober you up: this news is from 2022, and in four years, nothing fundamentally has changed in the industry.
I won't rehash the press release. Let's break down what this "breakthrough" really means, why it's still not in clinics, and who actually benefits from the hype around autonomous surgery.
[The Gist]: What's Really Happening
In reality, there was no "fully autonomous" surgery on May 30, 2026. The news that media outlets are reporting (the STAR robot from Johns Hopkins University performed laparoscopic bowel surgery on a pig) was published in the journal Science Robotics in January 2022. What is now being touted as a "breakthrough" is either a reprint of old material or deliberate date manipulation.
But even the original 2022 study was not "fully autonomous." Yes, STAR (Smart Tissue Autonomous Robot) demonstrated impressive results: when suturing two ends of the small intestine (intestinal anastomosis) in four pigs, its results in consistency and suture accuracy were statistically better than those of experienced surgeons. The machine doesn't tremble, doesn't get tired, and every stitch is perfect.
But here's the key: STAR used a structured-light 3D visualization system and a machine learning algorithm for real-time tissue tracking. However, even the developers admit that "human intervention was minimal," not zero. This is level 3 autonomy on a scale of 1 to 5 — "conditional autonomy," where the robot performs the task but a human supervises.
Insight not in the news: The current race is not for full autonomy (still 10-15 years away), but for expanding indications for existing robots (Intuitive da Vinci, CMR Versius, Medtronic Hugo) and for new niches — for example, endoscopic robotic surgery without incisions.
[Timeline and Context]
Let's set the record straight. Here is the real timeline of events, showing where we actually stand:
- January 2022: Publication in Science Robotics. STAR performs anastomosis on pigs without direct human control, but with "minimal intervention." Results are impressive, but this is a proof-of-concept in animals.
- 2024–2025: Major players are focused elsewhere. CMR Surgical receives De Novo from FDA in October 2024, and then in December 2025, 510(k) for the second-generation Versius Plus for cholecystectomy. They have already treated over 45,000 patients worldwide.
- May 2026 (literally last week): Intuitive Surgical announces over 100 updates for da Vinci 5, including Force Feedback (instruments now usable 15 times instead of 6), improved telepresence, and a digital ruler for intraoperative measurements.
- May 22, 2026: Medtronic announces expanded indications for Hugo RAS (already approved in the US for urology, more to come).
- May 30, 2026 (today): Media "recall" STAR from 2022.
Conclusion: Today's "news" is not a breakthrough but a historical reference. The industry is moving in a completely different direction: not toward full autonomy (legally and technically still science fiction), but toward expanding access to robotic surgery through modular systems, reducing procedure costs, and increasing the number of trained surgeons.
[Who Wins and Who Loses]
Winners (real, not from the news):
- Intuitive Surgical (NASDAQ: ISRG). They have over 1,400 installed da Vinci 5 systems worldwide, performed over 380,000 procedures, and trained over 12,800 surgeons. Their "razor and blades" business model (system + consumables) generates billions. They are not afraid of STAR because they understand: regulators will not approve full autonomy in humans until at least 2035. Instead, they improve Force Feedback, telepresence, and safety.
- CMR Surgical. They are the second most used robot for soft tissue globally. Their modular architecture (arms can be moved between operating rooms) addresses the main hospital pain point: one robot for multiple rooms. FDA clearance obtained, commercialization in the US began in 2026.
- EndoQuest Robotics. Their quiet victory: FDA approval for the final stage of the pivotal PARADIGM trial. They are developing robotic endoscopy (through the mouth or anus, without incisions) to remove polyps and tumors in the GI tract. This is a market da Vinci doesn't touch. Their partnership with Nvidia (IGX Thor platform) adds AI power.
Losers:
- Johnson & Johnson Ottava. They submitted a de novo request to the FDA in January 2026, but still no approval. While Intuitive and CMR are selling, J&J is only hoping.
- Small startups promising "full autonomy." Their time has not yet come. Investors have realized: the regulatory path for autonomous surgery is 5-10 times longer and more expensive than for assisted surgery. Money flows to platforms that can be sold today.
[What the Media Isn't Saying]
Omission #1: STAR 2022 is not for laparoscopy as we know it.
In the original 2022 paper, the robot worked through a fairly large incision. For true laparoscopy (through several small punctures), a completely different mechanics is needed. The researchers admit their system is far from clinical application in humans.
Omission #2: The legal problem of "liability" remains unsolved.
If an autonomous robot makes a mistake, who is at fault? The surgeon who activated it? The manufacturer? The algorithm developer? The FDA and European regulators have no clear answer. Until this is resolved, no insurance company will pay for "autonomous" surgeries, and no hospital will take on such risk.
Omission #3: The surgeon shortage is not about "replacement" but "augmentation."
Yes, the US surgeon shortage could reach 86,000 by 2036. But the solution is not robots without humans, but robots that allow one surgeon to perform more operations faster and with better results. That's exactly what da Vinci with Force Feedback and improved ergonomics does. STAR with its anastomosis is a cool lab toy, but for a real operating room with emergency bleeding and anatomical variations, it's not ready.
[Forecast: Next 30 Days and 90 Days]
Next 30 days:
- News from Intuitive Surgical. They announced that in June 2026, they will begin a phased rollout of updates for da Vinci 5 (mobile login, SimNow 2 simulations). Expect press releases about first implementations at major centers (Mayo Clinic, Cleveland Clinic).
- CMR Surgical will announce the first US installation of Versius Plus. FDA clearance obtained in December 2025, commercialization began in 2026. First systems should have been delivered to pilot centers.
Next 90 days:
- Johnson & Johnson will receive (or not) an FDA decision on Ottava. This is a key moment. If FDA approves, J&J bursts into the market with a strong brand and distribution. If not, Intuitive strengthens its monopoly.
- Publication of PARADIGM trial results from EndoQuest. Their final pivotal trial on 50 patients at five leading centers should conclude. If data are good, a de novo request to the FDA by end of 2026, and the endoscopic robotic surgery market (no incisions!) will get its first player.
- The media wave about "autonomous surgery" will subside. Once investors realize the STAR news is from 2022, focus will return to real growth drivers: Intuitive (ISRG), CMR (private), Medtronic (MDT), and EndoQuest.
Insider verdict: The current news is information noise. Don't waste time on it. The real revolution in surgery is happening not in labs, but in operating rooms, where da Vinci 5 with Force Feedback lets the surgeon "feel" tissues as in open surgery, and Versius Plus makes robotic surgery accessible to small hospitals with a budget of $500,000 instead of $2 million.
If you're an investor — look at companies that are already selling their systems and expanding indications. If you're a surgeon — learn to work with robots, because in 5-7 years, without this skill, you'll be uncompetitive. Full autonomy? Give it another 10-15 years and, crucially, a solution to the legal liability problem.
— Editorial Team
